 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Market Growth 2026-2032
The global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material market size is predicted to grow from US$ 4014 million in 2025 to US$ 8913 million in 2032; it is expected t... もっと見る
SummaryThe global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material market size is predicted to grow from US$ 4014 million in 2025 to US$ 8913 million in 2032; it is expected to grow at a CAGR of 12.1% from 2026 to 2032.Artificial substitutes for rare and endangered animal-derived medicinal materials refer to products developed through chemical synthesis or biotechnological approaches (including synthetic biology, bionics, cell engineering, etc.) that partially or fully replicate the efficacy of natural rare and endangered animal-derived medicinal materials (such as musk, bezoar, tiger bone, bear bile powder, antelope horn, pangolin scales, etc.), serving as raw material supplies for the production of Chinese patent medicines. These artificial substitutes are filed under Category 1.3 of the Chinese herbal medicine registration classification (“new medicinal materials and their preparations”) and are approved for market after pharmaceutical, pharmacological/toxicological, and clinical studies demonstrate comparability with natural materials. The core value lies in protecting wildlife resources while ensuring raw material supply security for well-established Chinese patent medicines (such as Angong Niuhuang Wan, Shexiang Baoxin Wan, Pien Tze Huang, etc.). The artificial substitutes for rare and endangered animal-derived medicinal materials are transitioning from monopoly to a structure of intensified competition and regulatory bottlenecks. On pricing, new entrants in in vitro cultivated bezoar (Baiyunshan Caizhilin, Yunnan Pharmaceutical Group, Sichuan Shennong, etc.) have quoted below RMB 130,000/kg, putting pressure on former sole supplier Jianmin Dapeng’s pricing system; artificial musk remains exclusively priced by Beijing Lianxin with stable terminal prices; artificial tiger bone powder is exclusively supplied by Ginwa Enterprise with no price erosion. Gross margins diverge sharply: Jianmin Dapeng’s in vitro cultivated bezoar achieves over RMB 1.5 million net profit per ton, contributing 35%-40% of Jianmin Group’s gross margin, yet faces downward pressure as competition intensifies; Beijing Lianxin maintains high margins on its exclusive artificial musk license; Ginwa Enterprise’s artificial tiger bone powder enjoys stable margins due to classified formula and patent protection. Downstream applications are concentrated in emergency Chinese patent medicines (Angong Niuhuang Wan, Shexiang Baoxin Wan), chronic disease management (Pien Tze Huang, Jintiange Capsule), and over 300 classical formulas, with extremely rigid demand. Incremental demand comes from policy-driven substitution (NMPA’s 2025 announcement supporting substitutes for pangolin scales, antelope horn, bear bile powder, etc.) and resource scarcity-driven replacement. Upstream includes raw material supply (natural musk, natural bezoar, bear bile) and technology R&D (synthetic biology, biomimetic synthesis); downstream includes pharmaceutical manufacturers (Tongrentang, Guangyuyuan, Pien Tze Huang, etc.) and medical institutions. The landscape is tri-tiered: artificial musk (Beijing Lianxin monopoly, >99% substitution rate, saturated market); in vitro cultivated bezoar (moving from Jianmin Dapeng sole supplier to at least six competitors, capacity expansion 10-20x, initial price war); artificial tiger bone powder (Ginwa Enterprise exclusive, steady growth); bear bile/antelope horn/pangolin scales (regulatory bottleneck: Yanbian Bear Farm, Yunnan Dali Ruihe, etc. have filed supplementary applications; Chongqing Jize and Zhongshan Bailing have manufacturing capabilities but none yet approved; no legal entity holds production qualification for antelope horn or pangolin substitutes). Key uncertainties lie in approval timelines – despite CDE’s technical guidelines, actual approval dates, clinical equivalence validation standards, and conditional approval pathways remain unclear. Additionally, capacity release schedules and price war intensity will reshape value distribution in the cultivated bezoar segment. Conclusion: The artificial substitutes sector is driven by three forces – irreversible resource depletion, accelerating policy-mandated substitution, and mature technology pathways. The core characteristics are monopoly in mature categories (musk, tiger bone), intensifying competition in scaling categories (bezoar), and regulatory bottlenecks in blank categories (bear bile, antelope horn, pangolin). The greatest value variable is not technical feasibility but who gains approval first, under what standards, and how capacity and cost advantages translate into market share post-approval. LP Information, Inc. (LPI) ' newest research report, the “Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Industry Forecast” looks at past sales and reviews total world Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material sales in 2025, providing a comprehensive analysis by region and market sector of projected Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material sales for 2026 through 2032. With Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material industry. This Insight Report provides a comprehensive analysis of the global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material. This report presents a comprehensive overview, market shares, and growth opportunities of Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: Musk Bezoar Tiger Bone Bear Bile Powder Antelope Horn Pangolin Scales Others Segmentation by Process: Chemical Synthesis Biosynthesis / Synthetic Biology In Vitro Cultivation Biomimetic / Bionic Synthesis Economic Animal Byproduct Synergistic Compatibility Segmentation by Application: Acute Critical Care Chinese Patent Medicines Chronic Disease Management Chinese Patent Medicines Classical Prescriptions / Traditional Formulas Preparation Intermediates / APIs Others This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration. Beijing Lianxin Pharmaceutical Shandong Hongjitang Pharmaceutical Firmenich Givaudan International Flavors & Fragrances (IFF) Symrise Takasago International Wuhan Jianmin Dapeng Pharmaceutical HEC (HEC Pharma) Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Yunnan Pharmaceutical Group Sichuan Shennong Pharmaceutical Jiangsu Binghetang Pharmaceutical Baicaotang Pharmaceutical Koyuan Pharmaceutical Zhongxing Mushroom (002772) Yichang Dongguang Winterworm Summerherb Ecological Breeding Xinshida Biotechnology Guangdong Rundongxia Health Industry SnowRong Bio (300511) Beijing Yanji Biotechnology Qinghai Digital Healing Intelligent Technology Monolis Chongqing Jize Biotechnology Zhongshan Bailing Biotechnology Yanbian Bear Farm Yunnan Tianyou Xiongye Pharmaceutical Yunnan Dali Ruihe Pharmaceutical Heilongjiang Yebao Pharmaceutical Tieling Shenxiong Pharmaceutical Guangzhou Jinxiong Pharmaceutical Lanzhou Fengchun Sheye Technology Xinjiang Baokang Pharmaceutical Hunan Huana Pharmaceutical (688799) Fujian Zhongyi Pharmaceutical Anhui Kebao Bioengineering Shaanxi Jichuang Huizhi Biotechnology BASF Soda Aromatic ACS International Triveni Chemicals Puyang Yuantai Fine Chemicals Chance Sun Import & Export Wanxiang Technology NHU Puyang Ouya Aromas Anhui Jinhe Industrial Jiayuan Fragrances Daewoong Chemical Mitsubishi Tanabe Pharma ICE Group PharmaZell Dipharma Francis Tsumura Kracie Tochimoto Itoh Kampo Kokando Ohmine Key Questions Addressed in this Report What is the 10-year outlook for the global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material market? What factors are driving Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material market opportunities vary by end market size? How does Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material break out by Type, by Application? Table of Contents1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Annual Sales 2021-2032 2.1.2 World Current & Future Analysis for Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material by Geographic Region, 2021, 2025 & 2032 2.1.3 World Current & Future Analysis for Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material by Country/Region, 2021, 2025 & 2032 2.2 Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Segment by Type 2.2.1 Musk 2.2.2 Bezoar 2.2.3 Tiger Bone 2.2.4 Bear Bile Powder 2.2.5 Antelope Horn 2.2.6 Pangolin Scales 2.2.7 Others 2.2.8 Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Type 2.2.8.1 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Market Share by Type (2021-2026) 2.2.8.2 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue and Market Share by Type (2021-2026) 2.2.8.3 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sale Price by Type (2021-2026) 2.3 Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Segment by Process 2.3.1 Chemical Synthesis 2.3.2 Biosynthesis / Synthetic Biology 2.3.3 In Vitro Cultivation 2.3.4 Biomimetic / Bionic Synthesis 2.3.5 Economic Animal Byproduct Synergistic Compatibility 2.3.6 Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Process 2.3.6.1 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Market Share by Process (2021-2026) 2.3.6.2 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue and Market Share by Process (2021-2026) 2.3.6.3 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sale Price by Process (2021-2026) 2.4 Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Segment by Application 2.4.1 Acute Critical Care Chinese Patent Medicines 2.4.2 Chronic Disease Management Chinese Patent Medicines 2.4.3 Classical Prescriptions / Traditional Formulas 2.4.4 Preparation Intermediates / APIs 2.4.5 Others 2.4.6 Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Application 2.4.6.1 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sale Market Share by Application (2021-2026) 2.4.6.2 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue and Market Share by Application (2021-2026) 2.4.6.3 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sale Price by Application (2021-2026) 3 Global by Company 3.1 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Breakdown Data by Company 3.1.1 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Annual Sales by Company (2021-2026) 3.1.2 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Market Share by Company (2021-2026) 3.2 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Annual Revenue by Company (2021-2026) 3.2.1 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue by Company (2021-2026) 3.2.2 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue Market Share by Company (2021-2026) 3.3 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sale Price by Company 3.4 Key Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Location Distribution 3.4.2 Players Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026) 3.6 New Products and Potential Entrants 3.7 Market M&A Activity & Strategy 4 World Historic Review for Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material by Geographic Region 4.1 World Historic Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Market Size by Geographic Region (2021-2026) 4.1.1 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Annual Sales by Geographic Region (2021-2026) 4.1.2 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Annual Revenue by Geographic Region (2021-2026) 4.2 World Historic Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Market Size by Country/Region (2021-2026) 4.2.1 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Annual Sales by Country/Region (2021-2026) 4.2.2 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Annual Revenue by Country/Region (2021-2026) 4.3 Americas Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Growth 4.4 APAC Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Growth 4.5 Europe Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Growth 4.6 Middle East & Africa Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Growth 5 Americas 5.1 Americas Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Country 5.1.1 Americas Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Country (2021-2026) 5.1.2 Americas Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue by Country (2021-2026) 5.2 Americas Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Type (2021-2026) 5.3 Americas Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Application (2021-2026) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Region 6.1.1 APAC Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Region (2021-2026) 6.1.2 APAC Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue by Region (2021-2026) 6.2 APAC Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Type (2021-2026) 6.3 APAC Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Application (2021-2026) 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material by Country 7.1.1 Europe Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Country (2021-2026) 7.1.2 Europe Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue by Country (2021-2026) 7.2 Europe Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Type (2021-2026) 7.3 Europe Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Application (2021-2026) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material by Country 8.1.1 Middle East & Africa Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Country (2021-2026) 8.1.2 Middle East & Africa Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue by Country (2021-2026) 8.2 Middle East & Africa Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Type (2021-2026) 8.3 Middle East & Africa Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Application (2021-2026) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material 10.3 Manufacturing Process Analysis of Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material 10.4 Industry Chain Structure of Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Distributors 11.3 Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Customer 12 World Forecast Review for Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material by Geographic Region 12.1 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Market Size Forecast by Region 12.1.1 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Forecast by Region (2027-2032) 12.1.2 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Annual Revenue Forecast by Region (2027-2032) 12.2 Americas Forecast by Country (2027-2032) 12.3 APAC Forecast by Region (2027-2032) 12.4 Europe Forecast by Country (2027-2032) 12.5 Middle East & Africa Forecast by Country (2027-2032) 12.6 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Forecast by Type (2027-2032) 12.7 Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Forecast by Application (2027-2032) 13 Key Players Analysis 13.1 Beijing Lianxin Pharmaceutical 13.1.1 Beijing Lianxin Pharmaceutical Company Information 13.1.2 Beijing Lianxin Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.1.3 Beijing Lianxin Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.1.4 Beijing Lianxin Pharmaceutical Main Business Overview 13.1.5 Beijing Lianxin Pharmaceutical Latest Developments 13.2 Shandong Hongjitang Pharmaceutical 13.2.1 Shandong Hongjitang Pharmaceutical Company Information 13.2.2 Shandong Hongjitang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.2.3 Shandong Hongjitang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.2.4 Shandong Hongjitang Pharmaceutical Main Business Overview 13.2.5 Shandong Hongjitang Pharmaceutical Latest Developments 13.3 Firmenich 13.3.1 Firmenich Company Information 13.3.2 Firmenich Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.3.3 Firmenich Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.3.4 Firmenich Main Business Overview 13.3.5 Firmenich Latest Developments 13.4 Givaudan 13.4.1 Givaudan Company Information 13.4.2 Givaudan Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.4.3 Givaudan Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.4.4 Givaudan Main Business Overview 13.4.5 Givaudan Latest Developments 13.5 International Flavors & Fragrances (IFF) 13.5.1 International Flavors & Fragrances (IFF) Company Information 13.5.2 International Flavors & Fragrances (IFF) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.5.3 International Flavors & Fragrances (IFF) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.5.4 International Flavors & Fragrances (IFF) Main Business Overview 13.5.5 International Flavors & Fragrances (IFF) Latest Developments 13.6 Symrise 13.6.1 Symrise Company Information 13.6.2 Symrise Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.6.3 Symrise Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.6.4 Symrise Main Business Overview 13.6.5 Symrise Latest Developments 13.7 Takasago International 13.7.1 Takasago International Company Information 13.7.2 Takasago International Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.7.3 Takasago International Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.7.4 Takasago International Main Business Overview 13.7.5 Takasago International Latest Developments 13.8 Wuhan Jianmin Dapeng Pharmaceutical 13.8.1 Wuhan Jianmin Dapeng Pharmaceutical Company Information 13.8.2 Wuhan Jianmin Dapeng Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.8.3 Wuhan Jianmin Dapeng Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.8.4 Wuhan Jianmin Dapeng Pharmaceutical Main Business Overview 13.8.5 Wuhan Jianmin Dapeng Pharmaceutical Latest Developments 13.9 HEC (HEC Pharma) 13.9.1 HEC (HEC Pharma) Company Information 13.9.2 HEC (HEC Pharma) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.9.3 HEC (HEC Pharma) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.9.4 HEC (HEC Pharma) Main Business Overview 13.9.5 HEC (HEC Pharma) Latest Developments 13.10 Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) 13.10.1 Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Company Information 13.10.2 Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.10.3 Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.10.4 Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Main Business Overview 13.10.5 Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Latest Developments 13.11 Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) 13.11.1 Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Company Information 13.11.2 Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.11.3 Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.11.4 Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Main Business Overview 13.11.5 Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Latest Developments 13.12 Yunnan Pharmaceutical Group 13.12.1 Yunnan Pharmaceutical Group Company Information 13.12.2 Yunnan Pharmaceutical Group Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.12.3 Yunnan Pharmaceutical Group Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.12.4 Yunnan Pharmaceutical Group Main Business Overview 13.12.5 Yunnan Pharmaceutical Group Latest Developments 13.13 Sichuan Shennong Pharmaceutical 13.13.1 Sichuan Shennong Pharmaceutical Company Information 13.13.2 Sichuan Shennong Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.13.3 Sichuan Shennong Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.13.4 Sichuan Shennong Pharmaceutical Main Business Overview 13.13.5 Sichuan Shennong Pharmaceutical Latest Developments 13.14 Jiangsu Binghetang Pharmaceutical 13.14.1 Jiangsu Binghetang Pharmaceutical Company Information 13.14.2 Jiangsu Binghetang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.14.3 Jiangsu Binghetang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.14.4 Jiangsu Binghetang Pharmaceutical Main Business Overview 13.14.5 Jiangsu Binghetang Pharmaceutical Latest Developments 13.15 Baicaotang Pharmaceutical 13.15.1 Baicaotang Pharmaceutical Company Information 13.15.2 Baicaotang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.15.3 Baicaotang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.15.4 Baicaotang Pharmaceutical Main Business Overview 13.15.5 Baicaotang Pharmaceutical Latest Developments 13.16 Koyuan Pharmaceutical 13.16.1 Koyuan Pharmaceutical Company Information 13.16.2 Koyuan Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.16.3 Koyuan Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.16.4 Koyuan Pharmaceutical Main Business Overview 13.16.5 Koyuan Pharmaceutical Latest Developments 13.17 Zhongxing Mushroom (002772) 13.17.1 Zhongxing Mushroom (002772) Company Information 13.17.2 Zhongxing Mushroom (002772) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.17.3 Zhongxing Mushroom (002772) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.17.4 Zhongxing Mushroom (002772) Main Business Overview 13.17.5 Zhongxing Mushroom (002772) Latest Developments 13.18 Yichang Dongguang Winterworm Summerherb Ecological Breeding 13.18.1 Yichang Dongguang Winterworm Summerherb Ecological Breeding Company Information 13.18.2 Yichang Dongguang Winterworm Summerherb Ecological Breeding Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.18.3 Yichang Dongguang Winterworm Summerherb Ecological Breeding Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.18.4 Yichang Dongguang Winterworm Summerherb Ecological Breeding Main Business Overview 13.18.5 Yichang Dongguang Winterworm Summerherb Ecological Breeding Latest Developments 13.19 Xinshida Biotechnology 13.19.1 Xinshida Biotechnology Company Information 13.19.2 Xinshida Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.19.3 Xinshida Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.19.4 Xinshida Biotechnology Main Business Overview 13.19.5 Xinshida Biotechnology Latest Developments 13.20 Guangdong Rundongxia Health Industry 13.20.1 Guangdong Rundongxia Health Industry Company Information 13.20.2 Guangdong Rundongxia Health Industry Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.20.3 Guangdong Rundongxia Health Industry Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.20.4 Guangdong Rundongxia Health Industry Main Business Overview 13.20.5 Guangdong Rundongxia Health Industry Latest Developments 13.21 SnowRong Bio (300511) 13.21.1 SnowRong Bio (300511) Company Information 13.21.2 SnowRong Bio (300511) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.21.3 SnowRong Bio (300511) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.21.4 SnowRong Bio (300511) Main Business Overview 13.21.5 SnowRong Bio (300511) Latest Developments 13.22 Beijing Yanji Biotechnology 13.22.1 Beijing Yanji Biotechnology Company Information 13.22.2 Beijing Yanji Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.22.3 Beijing Yanji Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.22.4 Beijing Yanji Biotechnology Main Business Overview 13.22.5 Beijing Yanji Biotechnology Latest Developments 13.23 Qinghai Digital Healing Intelligent Technology 13.23.1 Qinghai Digital Healing Intelligent Technology Company Information 13.23.2 Qinghai Digital Healing Intelligent Technology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.23.3 Qinghai Digital Healing Intelligent Technology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.23.4 Qinghai Digital Healing Intelligent Technology Main Business Overview 13.23.5 Qinghai Digital Healing Intelligent Technology Latest Developments 13.24 Monolis 13.24.1 Monolis Company Information 13.24.2 Monolis Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.24.3 Monolis Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.24.4 Monolis Main Business Overview 13.24.5 Monolis Latest Developments 13.25 Chongqing Jize Biotechnology 13.25.1 Chongqing Jize Biotechnology Company Information 13.25.2 Chongqing Jize Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.25.3 Chongqing Jize Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.25.4 Chongqing Jize Biotechnology Main Business Overview 13.25.5 Chongqing Jize Biotechnology Latest Developments 13.26 Zhongshan Bailing Biotechnology 13.26.1 Zhongshan Bailing Biotechnology Company Information 13.26.2 Zhongshan Bailing Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.26.3 Zhongshan Bailing Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.26.4 Zhongshan Bailing Biotechnology Main Business Overview 13.26.5 Zhongshan Bailing Biotechnology Latest Developments 13.27 Yanbian Bear Farm 13.27.1 Yanbian Bear Farm Company Information 13.27.2 Yanbian Bear Farm Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.27.3 Yanbian Bear Farm Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.27.4 Yanbian Bear Farm Main Business Overview 13.27.5 Yanbian Bear Farm Latest Developments 13.28 Yunnan Tianyou Xiongye Pharmaceutical 13.28.1 Yunnan Tianyou Xiongye Pharmaceutical Company Information 13.28.2 Yunnan Tianyou Xiongye Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.28.3 Yunnan Tianyou Xiongye Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.28.4 Yunnan Tianyou Xiongye Pharmaceutical Main Business Overview 13.28.5 Yunnan Tianyou Xiongye Pharmaceutical Latest Developments 13.29 Yunnan Dali Ruihe Pharmaceutical 13.29.1 Yunnan Dali Ruihe Pharmaceutical Company Information 13.29.2 Yunnan Dali Ruihe Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.29.3 Yunnan Dali Ruihe Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.29.4 Yunnan Dali Ruihe Pharmaceutical Main Business Overview 13.29.5 Yunnan Dali Ruihe Pharmaceutical Latest Developments 13.30 Heilongjiang Yebao Pharmaceutical 13.30.1 Heilongjiang Yebao Pharmaceutical Company Information 13.30.2 Heilongjiang Yebao Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.30.3 Heilongjiang Yebao Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.30.4 Heilongjiang Yebao Pharmaceutical Main Business Overview 13.30.5 Heilongjiang Yebao Pharmaceutical Latest Developments 13.31 Tieling Shenxiong Pharmaceutical 13.31.1 Tieling Shenxiong Pharmaceutical Company Information 13.31.2 Tieling Shenxiong Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.31.3 Tieling Shenxiong Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.31.4 Tieling Shenxiong Pharmaceutical Main Business Overview 13.31.5 Tieling Shenxiong Pharmaceutical Latest Developments 13.32 Guangzhou Jinxiong Pharmaceutical 13.32.1 Guangzhou Jinxiong Pharmaceutical Company Information 13.32.2 Guangzhou Jinxiong Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.32.3 Guangzhou Jinxiong Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.32.4 Guangzhou Jinxiong Pharmaceutical Main Business Overview 13.32.5 Guangzhou Jinxiong Pharmaceutical Latest Developments 13.33 Lanzhou Fengchun Sheye Technology 13.33.1 Lanzhou Fengchun Sheye Technology Company Information 13.33.2 Lanzhou Fengchun Sheye Technology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.33.3 Lanzhou Fengchun Sheye Technology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.33.4 Lanzhou Fengchun Sheye Technology Main Business Overview 13.33.5 Lanzhou Fengchun Sheye Technology Latest Developments 13.34 Xinjiang Baokang Pharmaceutical 13.34.1 Xinjiang Baokang Pharmaceutical Company Information 13.34.2 Xinjiang Baokang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.34.3 Xinjiang Baokang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.34.4 Xinjiang Baokang Pharmaceutical Main Business Overview 13.34.5 Xinjiang Baokang Pharmaceutical Latest Developments 13.35 Hunan Huana Pharmaceutical (688799) 13.35.1 Hunan Huana Pharmaceutical (688799) Company Information 13.35.2 Hunan Huana Pharmaceutical (688799) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.35.3 Hunan Huana Pharmaceutical (688799) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.35.4 Hunan Huana Pharmaceutical (688799) Main Business Overview 13.35.5 Hunan Huana Pharmaceutical (688799) Latest Developments 13.36 Fujian Zhongyi Pharmaceutical 13.36.1 Fujian Zhongyi Pharmaceutical Company Information 13.36.2 Fujian Zhongyi Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.36.3 Fujian Zhongyi Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.36.4 Fujian Zhongyi Pharmaceutical Main Business Overview 13.36.5 Fujian Zhongyi Pharmaceutical Latest Developments 13.37 Anhui Kebao Bioengineering 13.37.1 Anhui Kebao Bioengineering Company Information 13.37.2 Anhui Kebao Bioengineering Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.37.3 Anhui Kebao Bioengineering Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.37.4 Anhui Kebao Bioengineering Main Business Overview 13.37.5 Anhui Kebao Bioengineering Latest Developments 13.38 Shaanxi Jichuang Huizhi Biotechnology 13.38.1 Shaanxi Jichuang Huizhi Biotechnology Company Information 13.38.2 Shaanxi Jichuang Huizhi Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.38.3 Shaanxi Jichuang Huizhi Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.38.4 Shaanxi Jichuang Huizhi Biotechnology Main Business Overview 13.38.5 Shaanxi Jichuang Huizhi Biotechnology Latest Developments 13.39 BASF 13.39.1 BASF Company Information 13.39.2 BASF Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications 13.39.3 BASF Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales, Revenue, Price and Gross Margin (2021-2026) 13.39.4 BASF Main Business Overview 13.39.5 BASF Latest Developments List of Tables/GraphsList of TablesTable 1. Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions) Table 2. Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions) Table 3. Major Players of Musk Table 4. Major Players of Bezoar Table 5. Major Players of Tiger Bone Table 6. Major Players of Bear Bile Powder Table 7. Major Players of Antelope Horn Table 8. Major Players of Pangolin Scales Table 9. Major Players of Others Table 10. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Type (2021-2026) & (Tons) Table 11. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Market Share by Type (2021-2026) Table 12. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue by Type (2021-2026) & ($ million) Table 13. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue Market Share by Type (2021-2026) Table 14. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sale Price by Type (2021-2026) & (US$/Ton) Table 15. Major Players of Chemical Synthesis Table 16. Major Players of Biosynthesis / Synthetic Biology Table 17. Major Players of In Vitro Cultivation Table 18. Major Players of Biomimetic / Bionic Synthesis Table 19. Major Players of Economic Animal Byproduct Synergistic Compatibility Table 20. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Process (2021-2026) & (Tons) Table 21. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Market Share by Process (2021-2026) Table 22. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue by Process (2021-2026) & ($ million) Table 23. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue Market Share by Process (2021-2026) Table 24. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sale Price by Process (2021-2026) & (US$/Ton) Table 25. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sale by Application (2021-2026) & (Tons) Table 26. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sale Market Share by Application (2021-2026) Table 27. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue by Application (2021-2026) & ($ million) Table 28. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue Market Share by Application (2021-2026) Table 29. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sale Price by Application (2021-2026) & (US$/Ton) Table 30. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Company (2021-2026) & (Tons) Table 31. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Market Share by Company (2021-2026) Table 32. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue by Company (2021-2026) & ($ millions) Table 33. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue Market Share by Company (2021-2026) Table 34. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sale Price by Company (2021-2026) & (US$/Ton) Table 35. Key Manufacturers Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Producing Area Distribution and Sales Area Table 36. Players Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Products Offered Table 37. Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Concentration Ratio (CR3, CR5 and CR10) & (2024-2026) Table 38. New Products and Potential Entrants Table 39. Market M&A Activity & Strategy Table 40. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Geographic Region (2021-2026) & (Tons) Table 41. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Market Share Geographic Region (2021-2026) Table 42. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue by Geographic Region (2021-2026) & ($ millions) Table 43. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue Market Share by Geographic Region (2021-2026) Table 44. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Country/Region (2021-2026) & (Tons) Table 45. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Market Share by Country/Region (2021-2026) Table 46. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue by Country/Region (2021-2026) & ($ millions) Table 47. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue Market Share by Country/Region (2021-2026) Table 48. Americas Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Country (2021-2026) & (Tons) Table 49. Americas Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Market Share by Country (2021-2026) Table 50. Americas Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue by Country (2021-2026) & ($ millions) Table 51. Americas Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Type (2021-2026) & (Tons) Table 52. Americas Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Application (2021-2026) & (Tons) Table 53. APAC Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Region (2021-2026) & (Tons) Table 54. APAC Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Market Share by Region (2021-2026) Table 55. APAC Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue by Region (2021-2026) & ($ millions) Table 56. APAC Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Type (2021-2026) & (Tons) Table 57. APAC Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Application (2021-2026) & (Tons) Table 58. Europe Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Country (2021-2026) & (Tons) Table 59. Europe Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue by Country (2021-2026) & ($ millions) Table 60. Europe Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Type (2021-2026) & (Tons) Table 61. Europe Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Application (2021-2026) & (Tons) Table 62. Middle East & Africa Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Country (2021-2026) & (Tons) Table 63. Middle East & Africa Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue Market Share by Country (2021-2026) Table 64. Middle East & Africa Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Type (2021-2026) & (Tons) Table 65. Middle East & Africa Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales by Application (2021-2026) & (Tons) Table 66. Key Market Drivers & Growth Opportunities of Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Table 67. Key Market Challenges & Risks of Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Table 68. Key Industry Trends of Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Table 69. Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Raw Material Table 70. Key Suppliers of Raw Materials Table 71. Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Distributors List Table 72. Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Customer List Table 73. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Forecast by Region (2027-2032) & (Tons) Table 74. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue Forecast by Region (2027-2032) & ($ millions) Table 75. Americas Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Forecast by Country (2027-2032) & (Tons) Table 76. Americas Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Annual Revenue Forecast by Country (2027-2032) & ($ millions) Table 77. APAC Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Forecast by Region (2027-2032) & (Tons) Table 78. APAC Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Annual Revenue Forecast by Region (2027-2032) & ($ millions) Table 79. Europe Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Forecast by Country (2027-2032) & (Tons) Table 80. Europe Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue Forecast by Country (2027-2032) & ($ millions) Table 81. Middle East & Africa Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Forecast by Country (2027-2032) & (Tons) Table 82. Middle East & Africa Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue Forecast by Country (2027-2032) & ($ millions) Table 83. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Forecast by Type (2027-2032) & (Tons) Table 84. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue Forecast by Type (2027-2032) & ($ millions) Table 85. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales Forecast by Application (2027-2032) & (Tons) Table 86. Global Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Revenue Forecast by Application (2027-2032) & ($ millions) Table 87. Beijing Lianxin Pharmaceutical Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 88. Beijing Lianxin Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 89. Beijing Lianxin Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 90. Beijing Lianxin Pharmaceutical Main Business Table 91. Beijing Lianxin Pharmaceutical Latest Developments Table 92. Shandong Hongjitang Pharmaceutical Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 93. Shandong Hongjitang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 94. Shandong Hongjitang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 95. Shandong Hongjitang Pharmaceutical Main Business Table 96. Shandong Hongjitang Pharmaceutical Latest Developments Table 97. Firmenich Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 98. Firmenich Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 99. Firmenich Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 100. Firmenich Main Business Table 101. Firmenich Latest Developments Table 102. Givaudan Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 103. Givaudan Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 104. Givaudan Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 105. Givaudan Main Business Table 106. Givaudan Latest Developments Table 107. International Flavors & Fragrances (IFF) Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 108. International Flavors & Fragrances (IFF) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 109. International Flavors & Fragrances (IFF) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 110. International Flavors & Fragrances (IFF) Main Business Table 111. International Flavors & Fragrances (IFF) Latest Developments Table 112. Symrise Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 113. Symrise Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 114. Symrise Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 115. Symrise Main Business Table 116. Symrise Latest Developments Table 117. Takasago International Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 118. Takasago International Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 119. Takasago International Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 120. Takasago International Main Business Table 121. Takasago International Latest Developments Table 122. Wuhan Jianmin Dapeng Pharmaceutical Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 123. Wuhan Jianmin Dapeng Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 124. Wuhan Jianmin Dapeng Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 125. Wuhan Jianmin Dapeng Pharmaceutical Main Business Table 126. Wuhan Jianmin Dapeng Pharmaceutical Latest Developments Table 127. HEC (HEC Pharma) Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 128. HEC (HEC Pharma) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 129. HEC (HEC Pharma) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 130. HEC (HEC Pharma) Main Business Table 131. HEC (HEC Pharma) Latest Developments Table 132. Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 133. Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 134. Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 135. Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Main Business Table 136. Ginwa Enterprise (Xi‘an Ginwa Pharmaceutical Factory) Latest Developments Table 137. Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 138. Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 139. Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 140. Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Main Business Table 141. Guangzhou Baiyunshan Pharmaceutical (Caizhilin Pharmaceutical) Latest Developments Table 142. Yunnan Pharmaceutical Group Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 143. Yunnan Pharmaceutical Group Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 144. Yunnan Pharmaceutical Group Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 145. Yunnan Pharmaceutical Group Main Business Table 146. Yunnan Pharmaceutical Group Latest Developments Table 147. Sichuan Shennong Pharmaceutical Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 148. Sichuan Shennong Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 149. Sichuan Shennong Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 150. Sichuan Shennong Pharmaceutical Main Business Table 151. Sichuan Shennong Pharmaceutical Latest Developments Table 152. Jiangsu Binghetang Pharmaceutical Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 153. Jiangsu Binghetang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 154. Jiangsu Binghetang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 155. Jiangsu Binghetang Pharmaceutical Main Business Table 156. Jiangsu Binghetang Pharmaceutical Latest Developments Table 157. Baicaotang Pharmaceutical Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 158. Baicaotang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 159. Baicaotang Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 160. Baicaotang Pharmaceutical Main Business Table 161. Baicaotang Pharmaceutical Latest Developments Table 162. Koyuan Pharmaceutical Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 163. Koyuan Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 164. Koyuan Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 165. Koyuan Pharmaceutical Main Business Table 166. Koyuan Pharmaceutical Latest Developments Table 167. Zhongxing Mushroom (002772) Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 168. Zhongxing Mushroom (002772) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 169. Zhongxing Mushroom (002772) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 170. Zhongxing Mushroom (002772) Main Business Table 171. Zhongxing Mushroom (002772) Latest Developments Table 172. Yichang Dongguang Winterworm Summerherb Ecological Breeding Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 173. Yichang Dongguang Winterworm Summerherb Ecological Breeding Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 174. Yichang Dongguang Winterworm Summerherb Ecological Breeding Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 175. Yichang Dongguang Winterworm Summerherb Ecological Breeding Main Business Table 176. Yichang Dongguang Winterworm Summerherb Ecological Breeding Latest Developments Table 177. Xinshida Biotechnology Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 178. Xinshida Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 179. Xinshida Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 180. Xinshida Biotechnology Main Business Table 181. Xinshida Biotechnology Latest Developments Table 182. Guangdong Rundongxia Health Industry Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 183. Guangdong Rundongxia Health Industry Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 184. Guangdong Rundongxia Health Industry Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 185. Guangdong Rundongxia Health Industry Main Business Table 186. Guangdong Rundongxia Health Industry Latest Developments Table 187. SnowRong Bio (300511) Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 188. SnowRong Bio (300511) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 189. SnowRong Bio (300511) Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 190. SnowRong Bio (300511) Main Business Table 191. SnowRong Bio (300511) Latest Developments Table 192. Beijing Yanji Biotechnology Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 193. Beijing Yanji Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 194. Beijing Yanji Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 195. Beijing Yanji Biotechnology Main Business Table 196. Beijing Yanji Biotechnology Latest Developments Table 197. Qinghai Digital Healing Intelligent Technology Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 198. Qinghai Digital Healing Intelligent Technology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 199. Qinghai Digital Healing Intelligent Technology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 200. Qinghai Digital Healing Intelligent Technology Main Business Table 201. Qinghai Digital Healing Intelligent Technology Latest Developments Table 202. Monolis Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 203. Monolis Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 204. Monolis Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 205. Monolis Main Business Table 206. Monolis Latest Developments Table 207. Chongqing Jize Biotechnology Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 208. Chongqing Jize Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 209. Chongqing Jize Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 210. Chongqing Jize Biotechnology Main Business Table 211. Chongqing Jize Biotechnology Latest Developments Table 212. Zhongshan Bailing Biotechnology Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 213. Zhongshan Bailing Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 214. Zhongshan Bailing Biotechnology Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 215. Zhongshan Bailing Biotechnology Main Business Table 216. Zhongshan Bailing Biotechnology Latest Developments Table 217. Yanbian Bear Farm Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 218. Yanbian Bear Farm Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 219. Yanbian Bear Farm Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 220. Yanbian Bear Farm Main Business Table 221. Yanbian Bear Farm Latest Developments Table 222. Yunnan Tianyou Xiongye Pharmaceutical Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 223. Yunnan Tianyou Xiongye Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 224. Yunnan Tianyou Xiongye Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 225. Yunnan Tianyou Xiongye Pharmaceutical Main Business Table 226. Yunnan Tianyou Xiongye Pharmaceutical Latest Developments Table 227. Yunnan Dali Ruihe Pharmaceutical Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 228. Yunnan Dali Ruihe Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 229. Yunnan Dali Ruihe Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 230. Yunnan Dali Ruihe Pharmaceutical Main Business Table 231. Yunnan Dali Ruihe Pharmaceutical Latest Developments Table 232. Heilongjiang Yebao Pharmaceutical Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 233. Heilongjiang Yebao Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 234. Heilongjiang Yebao Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 235. Heilongjiang Yebao Pharmaceutical Main Business Table 236. Heilongjiang Yebao Pharmaceutical Latest Developments Table 237. Tieling Shenxiong Pharmaceutical Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 238. Tieling Shenxiong Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 239. Tieling Shenxiong Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 240. Tieling Shenxiong Pharmaceutical Main Business Table 241. Tieling Shenxiong Pharmaceutical Latest Developments Table 242. Guangzhou Jinxiong Pharmaceutical Basic Information, Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Manufacturing Base, Sales Area and Its Competitors Table 243. Guangzhou Jinxiong Pharmaceutical Artificial Substitute for Rare & Endangered Animal-Derived Medicinal Material Product Portfolios and Specifications Table 244. Guangzhou Jinxiong Pharmaceutical
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医薬）の最新刊レポート
LP Information社の 医薬品・ヘルスケア分野 での最新刊レポート
本レポートと同じKEY WORD（artificial）の最新刊レポート
よくあるご質問LP Information社はどのような調査会社ですか?LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
